Conferences

2023

Meurillon, V. Synthesis of 6-substituted quinolines as novel efflux pump inhibitors to overcome antimicrobial resistance,8th Drug Discovery Day,Lille, France,15th Dec. 2023

Fougiaxis, V. Exploiting the Potential of Kinetic Target-Guided Synthesis in Hit Identification against ERAP-Metalloproteases,8th Drug Discovery Day,Lille, France,15th Dec. 2023

Charton, J. Screening and Hit to lead optimization: case study on the 3CL protease of SARS-CoV-2,2nd Drug Discovery & Screening Symposium From bench to drug discovery,Paris, France,7th Dec. 2023

Leroux, F. Early ADME profiling with the ARIADNE platform toolbox,2nd Drug Discovery & Screening Symposium From bench to drug discovery,Paris, France,7th Dec. 2023

Willand, N. Teaching an old drug new tricks thanks to SMARt compounds, the 178th nobel symposium in chemistry : Tuberculosis and Antibiotic Resistance - From Basic Drug Discovery to Clinic,Stellenbosch, South Africa,23-27th Oct. 2023

Compagne, N. Optimization of a pyridylpiperazine series as a novel class of efflux pump inhibitors in E. coli to fight antimicrobial resistance,10th EFMC Young Medicinal Chemists’ Symposium Zagreb, Croatia,7th Sept. 2023

Flipo, M. Development of efflux pump inhibitors to overcome antimicrobial resistance,8th Scientific Meeting of the Institut Pasteur de Lille Marcq-en-Baroeul, France,5th Sept. 2023

Compagne, N., Vieira Da Cruz, A., Jiménez-Castellanos, J.-C., Deprez, B., Willand, N., Pos, K. M., Hartkoorn, R. C., & Flipo, M. Optimization of a pyridylpiperazine series as a novel class of efflux pump inhibitors in E. coli to fight antimicrobial resistance,30th SCT Young Research Fellows Meeting,Paris, France,1st-3rd Feb. 2023

Camberlein, V. Discovery of Pseudomonas aeruginosa elastase LasB inhibitors by in situ click chemistry,30th SCT Young Research Fellows Meeting,Paris, France,1st-3rd Feb. 2023

Charton, J., & Tailleux, A. TGR5 : vers la résolution d’un paradoxe,Conclusion seminar of CPER CTRL (Centre Transdisciplinaire de Recherche sur la Longévité),Lille, France,12th Janv. 2023

Deprez, B. Contexte(s) de la découverte du BVL-098 alpibectir,Conclusion seminar of CPER CTRL (Centre Transdisciplinaire de Recherche sur la Longévité),Lille, France,12th Janv. 2023

Villemagne, B. New Leads for TB,Conclusion seminar of CPER CTRL (Centre Transdisciplinaire de Recherche sur la Longévité),Lille, France,12th Janv. 2023

2022

Vigier, C. Elucidation of mechanism of action and target of alkylated fluoroquinolones presenting activity on Mycobacterium tuberculosis, using click-chemistry coupled to MS analysis.,7th Drug Discovery Day,Lille, France,16th Dec. 2022

Sierocki, P. Overcoming peptidic scaffolds' limitations using KTGS : Discovery of the 1st selective and druglike ERAP2 inhibitors,7th Drug Discovery Day,Lille, France,16th Dec. 2022

Ruggieri, F. A Three-step Process to Isolate Large Quantities of Bioactive Sesquiterpene Lactones from Chicorium intybus L. Roots,7th Drug Discovery Day,Lille, France,16th Dec. 2022

Compagne, N. Pyridylpiperazines as efflux pump inhibitors to overcome antimicrobial resistance,7th Drug Discovery Day,Lille, France,16th Dec. 2022

Chaibi, F. Z. Identification and optimization of new covalent reversible inhibitors of the 3CL protease of SARS-CoV-2,7th Drug Discovery Day,Lille, France,16th Dec. 2022

Boulloy, A. Small Molecules Aborting Resistance (SMARt) as a means to overcome antibiotic resistance in Tuberculosis.,7th Drug Discovery Day,Lille, France,16th Dec. 2022

Deprez-Poulain, R. MHC-I-opathies: Inhibitions des ERAPs comme nouvelle stratégie thérapeutique dans la maladie de Behcet et la chorioretinopathie de Birdshot, Colloque De la Recherche aux traitements dans les maladies rares,Fondation Maladies Rares,Institut Gernez Rieux, lille,17 Nov. 2022 Invited

Sierocki, P. Approche Guidée par la Cible pour la découverte de Médicament : Application à la protéine ERAP2 pour l'Immuno-Oncologie,Animation scientifique de la Faculté des Sciences de la Santé et du Sport - Webinar "Save Your Fridays",Lille, France,21th October 2022

Villemagne, B. Targeting the electron transport chain: a new paradigm in Antimycobacterial Drug Discovery,17ème congrès national de la SMF (Société Francaise de Microbiologie),Montpellier, France,5th October 2022 Invited.

Deprez, B. "All Models are Wrong, Some are Useful". The Medicinal Chemist is Never Better Than the Biological Models Available to Assess Compound Properties,9th EFMC Young Medicinal Chemists' Symposium,Nice, France,8-9th September 2022 Invited.

Deprez, B. Boosting « Chance and Necessity » with Experience and Molecular Creativity,XXVII EFMC International Symposium on Medicinal Chemistry,Nice, France,4-8th September 2022 Invited.

Deprez-Poulain, R. First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation,XXVII EFMC International Symposium on Medicinal Chemistry,Nice, France,4-8th september 2022 Invited.

Modesto J., R., Porras de Francisco, E., Baulard, A., Willand, N., Defert, O., Bourotte, M., & Pieren, M. Rejuvenating ethionamide for treatment of tuberculosis - TRICky, but possible,XXVII EFMC International Symposium on Medicinal Chemistry,Nice, France,4-8th september 2022

Deprez-Poulain, R. IDE and ERAP inhibitors discovered by KTGS and their use in therapeutics,GP2A 2022 - 30th Annual Conference,Dublin, IE,24th-26th Aug. 2022 Invited.

Sierocki, P. Overcoming peptidic scaffolds' limitations using KTGS : Discovery of the 1st selective and druglike ERAP2 inhibitors,29th SCT Young Research Fellows Meeting,Nantes, France,4-6th July 2022

Willand, N. Tricks to discover a STAR (Strategy To overcome Antimicrobial Resistance),29th SCT Young Research Fellows Meeting,Nantes, France,4-6th July 2022 Invited.

Villemagne, B. Design, development and synthesis of M.tuberculosis inhibitors,« Journée de l’Ecole Doctorale Normande de Chimie »,Caen, France,23th June 2022 Invited.

Villemagne, B. Development of nature-inspired tricyclic lactams as novel inhibitors of Mycobacterium tuberculosis respiratoty chain,7th Scientific Meeting of the Institut Pasteur de Lille Marcq-en-Baroeul, France,9th June 2022

2021

Kraupner, N. Identification of indole-based activators of insulin degrading enzyme,6th Drug Discovery Day,Lille, France,14th Dec. 2021

Dinh, C. P. Discovery of novel allosteric binding site of 5-lipoxygenase,6th Drug Discovery Day,Lille, France,14th Dec. 2021

Antraygues, K. Design, synthesis and biological evaluation of rifabutin prodrugs for the treatment of bacterial infections,6th Drug Discovery Day,Lille, France,14th Dec. 2021

Deprez, B. THERAPIDE, a story of drug repurposing in COVID19 : from bedside to bench to bedside in a year time,6th Scientific Meeting of the Institut Pasteur de Lille Marcq-en-Baroeul, France,14th Sept. 2021

Charton, J. Screening for the identification of new inhibitors of the 3CL protease of SARS-CoV-2,6th Scientific Meeting of the Institut Pasteur de Lille Marcq-en-Baroeul, France,14th Sept. 2021

Sierocki, P. Discovery & binding study of hERAP2 modulators identified via HTS,GP2A 2021 - 29th Annual Conference,Virtual conference,25th-27th Aug. 2021

Flipo, M., Villemagne, B., Brodin, P., Deprez, B., Baulard, A., & Willand, N. Fragment-based approaches to inhibit Mycobacterium tuberculosis targets,GP2A 2021 - 29th Annual Conference,Virtual conference,25th-27th Aug. 2021 Invited.

Baulard, A., Willand, N., Frita, R., Flipo, M., Deprez, B., Remuiñan, M., Mendoza-Losana, A., Rebollo, M. J., Pérez-Herrán, E., Barros, D., Trauner, A., Gagneux, S., Trebosc, V., Kemmer, C., Bourotte, M., Gitzinger, M., Dale, G. E., Pieren, M., & Lociuro, S. How to turn an old drug into a potent, rapidly bactericidal and safer drug: clinical candidate BVL-GSK098 overcomes resistance to and potentiates the activity of ethionamide by boosting ethionamide bioactivation in Mycobacterium tuberculosis,European Congress of Clinical Microbiology and Infectious Diseases - 31st ECCMID,Vienna, Austria,11h July. 2021

Maitre, T., Lociuro, S., Pieren, M., Chauffour, A., Fournier Le Ray, L., Aubry, A., Willand, N., Baulard, A., Remuiñan, M., Rullás, J., Dale, G. E., Gitzinger, M., & Veziris, N. Bactericidal activity of ethionamide alone and boosted by BVL-GSK098 in an acute murine model of tuberculosis,European Congress of Clinical Microbiology and Infectious Diseases - 31st ECCMID,Vienna, Austria,11h July. 2021

Deprez-Poulain, R. Kinetic target-guided synthesis et acides hydroxamiques des outils efficaces pour la drug-discovery ciblant les metalloproteases.,CEISAM, Nantes, France,26th Mar. 2021 Invited.

Brier, L. Discovery of new inhibitors of the SARS-CoV-2 3CL protease by High Throughput Screening,28th SCT Young Research Fellows Meeting,Paris, France,11th-12th Feb. 2021 flashtalk.

2020

Brier, L., Landry, V., Dumont, J., Warenghem, S., Herledan, A., Hanoulle, X., Belouzard, S., Dubuisson, J., Florence, L., Benoit, D., & Julie, C. Discovery of new inhibitors of the SARS-CoV-2 3CL protease by High Throughput Screening,5th Drug Discovery Day - Conception Synthèse Evaluation et Sélection du principe actif,Lille, France,16th Dec. 2020

Camberlein, V., Gealageas, R., Tabey-Fleau, C., Warenghem, S., Guillaume, V., Bosc, D., Florence, L., Benoit, d., & deprez-Poulain, R. Discovery of hERAP2 inhibitors by kinetic target-guided synthesis,5th Drug Discovery Day - Conception Synthèse Evaluation et Sélection du principe actif,Lille, France,16th Dec. 2020

Deprez-Poulain, R., Antigen presentation and pharmacological modulation of ERAPs for autoimmune diseases, including type 1 diabetes, Live Webinar on Webex Events,16th-17th June 2020 Invited.

Dreneau, A., Faion, L., Djaout, K., Prieri, M., Frita, R., Piveteau, C., Benoit, D., M., F., A., B., & Willand, N. Discovery, optimization and biological evaluation of the first boosters of the nitroimidazole anti-TB drug Pretomanid,27th SCT Young Research Fellow Meeting,Caen, France,29th-31st Janv 2020

Faion, L. Structure-activity relationship studies within the first chemical family of boosters of the nitroimidazole anti-tb drug pretomanid,27th SCT Young Research Fellows Meeting,Caen, France,29th - 31th jan. 2020 Flashtalk.

2019

Camberlein, V., Gealageas, R., Tabey-Fleau, C., Warenghem, S., Guillaume, V., Bosc, D., Leroux, F., Deprez, B., & Deprez-Poulain, R. Discovery of hERAP2 inhibitors by in situ click chemistry,4th Drug Discovery Day - From Concept to Scale up,Lille, France,17th Dec 2019

Lesire, L., Florence, L., Deprez-Poulain, R., & Benoit, D. Strategies to characterize the mechanism of action of a compound booster of anticancer therapies.,4th Drug Discovery Day - From Concept to Scale up,Lille, France,17th Dec 2019

Faion, L., Dreneau, A., Djaout, K., Prieri, M., Frita, R., Piveteau, C., Benoit, D., M., F., A., B., & Willand, N. Structure-Activity Relationship Studies Within The First Chemical Family Of Boosters Of The Nitroimidazole Anti-Tb Drug Pretomanid,4th Drug Discovery Day - From Concept to Scale up,Lille, France,17th Dec 2019

Deprez-Poulain, R. Validating new metalloproteases targets in drug discovery using small molecules,GDCh-Wissenschaftsforum Chemie,GDCh,Aachen, Germany,15th-18th Sept. 2019 Invited.

Faion, L. Structural optimization and biological evaluation of Mycobacterium tuberculosis MabA inhibitors,19eme Journées André Verbert,Lille, France,10th Sept. 2019 Flashtalk.

Lesire, L. Strategies to characterize the involvement of a protein in tumor cell survival.,19eme Journée André Verbert,Lille, France,10th Sept. 2019

Andres, M. New insights into a potential therapeutic target regulating Unfolded Protein Response and subsequent inflammation in liver and muscle,19eme Journée André Verbert,Lille, France,10th Sept. 2019

Willand, N. Nature-inspired molecules as a new source of hits,5th Scientific Meeting of the Institut Pasteur de Lille Marcq-en-Baroeul, France,20th June 2019

Deprez-Poulain, R. Kinetic Target-Guided Synthesis as a Tool for Drug-Discovery: Successes, Challenges and Applications to Metalloproteases,2nd Molecules Medicinal Chemistry Symposium,Barcelona, Spain,15th-17th May 2019 Invited.

Deprez, B., & Bouquet, C. Regards croisés: les coulisses d'une fondation de recherche,Conférencs 5à7,Institut Pasteur de Lille,5th Feb. 2019

Villoutreix, B. Web based chemoinformatics,ACS Spring 2019,Orlando, USA,2019

Lesire, L. Imaging & quantifying aggresome in an automated miniaturized microscopy assay.,Drug Discovery Day,Lille, France,18th jan. 2019


2018

Deprez-Poulain, R. Pharmacological modulation of antigen processing and presentation: new therapeutic approach for cancer and autoimmune diseases,4th Scientific Meeting of the Institut Pasteur de Lille,Marcq en Baroeul, France,18 Jun. 2018 Invited.

Charton, J. Topical Intestinal Agonists of the Bile Acid Receptor TGR5: Controlling Target Engagement by Innovative Molecular Engineering,54th RICT-ICMC Interfacing Chemical Biology and Drug Discovery,Strasbourg, France,4th-6th Jul. 2018 Invited.

Faion, L. Chemical modifications of Mycobacterium tuberculosis MabA inhibitors GP2A,26th GP2A – 32nd JFB,Asnelles sur mer, France.,13th-15th Jun. 2018 flash presentation

Faion, L. Chemical modifications of Mycobacterium tuberculosis MabA inhibitors,2e Journée de la Recherche de la Faculté de Pharmacie,Lille, France,11th Jul 2018 flash presentation

Lesire, L. Visualisation and quantification of cell aggresome in an automated miniaturized assay 2e Journée de la Recherche de la Faculté de Pharmacie,Lille, France,11th Jul 2018 flashtalk

Deprez-Poulain, R. Nouveaux médicaments du cancer et des maladies auto-immunes : dompter le système immunitaire à des fins thérapeutiques,Conférences 5à7 Médicaments,Institut Pasteur de Lille, France,17th Apr. 2018

Willand, N., Gitzinger, M., Deprez, B., & Baulard, A. R. New tricks for old drugs or how to outsmart Tuberculosis drug resistance with SMARt molecules,25th Young Research Fellow Meeting of the SCT,Orleans, France,5th-7th March 2018 Invited.


2017

Deprez, B. Creating, Varying and Selecting : the driving forces in drug discovery and chemical biology.,53rd International Conference on Medicinal Chemistry (RICT),Toulouse, FR,7th July 2017 Invited - Pierre Fabre Prize Lecture.

Charton, J., Tailleux, A., Staels, B., & Deprez, B. Développement d’agonistes topiques intestinaux du récepteur aux acides biliaires TGR5.,1ère Journée de la recherche de la Faculté de Pharmacie,Lille, FR,10th July 2017

Charton, J. Topical intestinal agonists of the bile acid receptor TGR5: controlling target engagement by innovative molecular engineering,3rd Scientific Meeting of the Institut Pasteur de Lille,Marcq-en-Baroeul, FR,2017

Deprez, B. Outsmarting Resistance,Conférence mycobactéries de la Société Française de Microbiologie,Montigny le Bretonneux, FR,30th May 2017 Invited.

Prieri, M., Probst, N. P., Frita, R., Bourotte, M., Deprez, B., Baulard, A., & Willand, N. Antitubercular Activity Study of Thioamide-Analogues in the presence of 1st and 2nd Generation of Ethionamide-Bosters BDM41906 and SMARt-420,Drug Discovery Day, Master Seminar,School of  Pharmacy, Lille, France,7th Dec. 2017

Deprez, B. Outsmarting Resistance in Tuberculosis SMARt Compounds: From Lead to Drug Candidate,Gordon Research Conference on Tuberculosis Drug Discovery and Development,Il Ciocco, IT,25th-30th Jun 2017 Invited.

Hermant, P., Piveteau, C., Bosc, D., Biela, A., Roignant, M., Deprez, B., & Deprez-Poulain, R. High-throughput profiling of esterases involved in hydroxamic acids hydrolysis,24th Young Research Fellow Meeting of the SCT,Châtenay Malabry, France,8th-10th February 2017.

Willand, N., Gitzinger, M., Deprez, B., & Baulard, A. Teaching old drugs new tricks: Reprogramming ethionamide’s bioactivation to fight multidrug resistant Mycobacterium tuberculosis.,253rd ACS National Meeting,San Francisco, CA, USA,April 5th 2017

2016

Deprez, B. Synthetic Biology of the Trojans:Overcoming Antibiotic Resistance by Reprogramming Bacterial Metabolism.,Medicinal Chemistry of Tropical Diseases XIIth SEQT Symposium;3rd Spanish, Portuguese, Brazilian Meeting,Madrid, Spain,17th-18th November 2016

Benoit, D. Screening : Source of discovery and innovation,European Lead Factory Meeting,Leiden, Belgium,12th Apr 2016 Invited.

Prevet, H., Flipo, M., Sperandio, O., Deprez, B., & Willand, N. New 3D-scaffolds for Fragment-based Lead Discovery: exploration of chemical space using highly functionalized spirohydantoins.,23rd Young Research Fellow Meeting of the SCT,Lille, France,15th-17th Feb. 2016.

Hoguet, V. Pharmacokinetic study of topical intestinal compounds,23rd Young Research Fellow Meeting of the SCT,15th-17th Feb. 2016, Flash presentation.

Hermant, P. Plasma and Microsomal Esterases involvement in the Metabolism of Hydroxamic acids in two species,23rd Young Research Fellow Meeting of the SCT,Lille, France,15th-17th Feb. 2016, Flash presentation.

2015

Willand, N. New tricks for old antibiotics,Université de Namur ASBL,Namur, Belgium,25th Sep. 2015, Invited.

Willand, N. Using Aged Drugs in New Ways, the Concept of Boosting Antibiotics,SCT-DMCCB Joint Meeting,Dijon, France,16th Oct. 2015, Invited.

Willand, N. New tricks for old drugs: using Fragment-based Drug Discovery and in silico screening for the discovery,Bilille In silico drug design One Day Symposium,Villeneuve d'Ascq, France,30th Nov. 2015, Invited.

Lasalle, M. Optimization and development of novel topical intestinal agonists of the bile acid receptor TGR5 for treatment of diabetes mellitus and associated metabolic diseases.,Cambridge, UK,16th-18th Sept. 2015, Flash communication.

Deprez-Poulain, R. From In situ Click to in vivo pharmacology: Effect of catalytic site inhibition of Insulin Degrading Enzyme on glucose tolerance,51st International Conference on Medicinal Chemistry,Avignon, France,1st-3rd July 2015, Invited.

Willand, N. Boosting antibiotics using transcriptional regulators: how an old drug can become a new drug,University of Durham,26th Feb 2015, Invited.

Lasalle, M., Tailleux, A., Hennuyer, N., Dubanchet, B., Belloy, L., Leroux, F., Staels, B., Gras-Masse, H., Deprez, B., & Charton, J. Design of agonists of the bile acid receptor TGR5,22nd YRFM of the SCT,Biocitech, Romainville, France,4th-6th Feb 2015.

Hermant, P. Hydroxamates as bioactives molecules: ADME properties, inhibitors of ERAPs, Inhibitors of IDE,2nd F3 Meeting,Ghent, Belgium,24th Mar 2015.

Herledan, A. Thermal Shift Assay Screening,2nd F3 Meeting,Ghent, Belgium,24th Mar 2015.

Lasalle, M. Optimization and development of novel agonists of the bile acid receptor TGR5 for treatment of diabetes mellitus and associated metabolic diseases,2nd F3 Meeting,Ghent, Belgium,24th Mar 2015.

Prevet, H. Design and Synthesis of 3-D fragments for fragment-based drug discovery (FBDD) approaches,2nd F3 Meeting,Ghent, Belgium,24th Mar 2015.

Villemagne, B. Fragment–based design, synthesis and development of inhibitors of the mycobacterial transcriptionnal repressor EthR. A new approach against tuberculosis,2nd F3 Meeting,Ghent, Belgium,24th Mar 2015.

2014

Deprez, B. Insulin Degrading Enzyme: deploying chemical concepts and tools to shed a new light on a highly conserved yet poorly understood protein.,Biocis,Chatenay Malabris, France,25th Sep. 2014, Invited.

Lasalle, M., Tailleux, A., Hennuyer, N., Dubanchet, B., Belloy, L., Leroux, F., Staels, B., Deprez, B., Gras-Masse, H., & Charton, J. Optimization and development of novel agonists of the bile acid receptor TGR5 for treatment of diabetes mellitus and associated metabolic diseases.,14th Journée André Verbert,Faculté de médecine, Pôle Recherche, Lille, France,11th Sep. 2014.

Lasalle, M. TGR5 agonists to treat diabetes mellitus,Rencontres de la Chimie, de la Biologie et de la Physique du PRIM,Lille, France,26th Jun. 2014.

Deprez, B., Deprez-Poulain, R., Willand, N., A., B., Leroux, F., Staels, B., Bosc, D., Ronco, C., & Villemagne, B. Structure-Based, Ligand Efficiency Driven Discovery and Early ADME, Learnings from two targets: EthR and Insulin Degrading Enzyme.,97th Canadian Chemistry Conference and Exhibition,Vancouver, Canada,1st-5th Jun 2014, Invited.

Willand, N., M., F., Villemagne, B., Piveteau, C., Wohlkönig, A., Wintjens, R., P., B., A., B., & Deprez, B. Boosting antibiotics through inhibition of transcriptional regulators: a new concept in the treatment of tuberculosis,SCI-Towards New Therapeutics for Diseases of the Developing World,GlaxoSmithKline, Tres Cantos, Madrid, Spain,11th-13th May 2014, Invited.

Henninot, A., Deprez, B., Urbain, R., Fontayne, A., & Beghyn, T. LCMS: a tool for pharmacologic screening.,XXIst Young Research Fellow Meeting of the SCT,Montpellier, France,24th-25th Mar. 2014, Flash Presentation.

Prevet, H., Flipo, M., Saas, L., Cocquerel, L., Dubuisson, J., Willand, N., Couturier, C., & Deprez, B. Discovery and synthesis of modulators of the CD81/CLDN-1 complex as new approach to prevent entry of the hepatitis C virus. XXIst Young Research Fellow Meeting of the SCT,Montpellier, France,24th-25th Mar 2014, Flash Presentation.

Deprez, B. Le médicament: infiniment petit, infiniment complexe, infiniment utile,5 à 7 Conférences Grand Public,Institut Pasteur de Lille, Lille, France,28th Jan 2014, Invited.

 

2013

Deprez, B. Découverte et Selection d'un candidat médicament. Stratégie et importance de l'intégration des données, le tableau de bord de la chimie médicinale,Seminaire Atherosclerose - Servier,Maffliers, France,3rd-5th Oct. 2013,Invited.

Deprez-Poulain, R. Hydroxamates as tools for the target validation of metalloproteases: Applications to malarial PfAM1 and human Insulin-Degrading Enzyme,National Centre for Scientific Research" Demokritos",Athens, Greece,30th October 2013, Invited.

Marechal, X., Bosc, D., Charton, J., Totobenazara, J., Berte, G., Verdelet, T., Dumont, J., Dassonneville, S., Gauriot, M., Paquet, C., Duplan, I., Herledan, A., Piveteau, C., Staels, B., Leroux, F., Hennuyer, N., Deprez, B., & Deprez-Poulain, R. Inhibition de la différenciation des myoblastes par des inhibiteurs de l’enzyme insulysine développés par click chemistry in situ.,Congrès SFBBM - GT Enzymes,Paris, France,4th-6th September 2013.

Deprez-Poulain, R., Berte, G., Bosc, D., Marechal, E., Gauriot, M., Hennuyer, N., Leroux, F., Charton, J., Lippens, G., Tang, W. J., Staels, B., & Deprez, B. X-ray Crystallography, Kinetic Target-guided synthesis and NMR to unravel the mode of action of insulin degrading enzyme modulators,NovAliX Conference,Strasbourg France,15th-18th October 2013.

Deprez-Poulain, R., Bosc, D., Leroux, F., Charton, J., Tang, W. J., & Deprez, B. Discovery and optimization of Insulin-Degrading Enzyme inhibitors by screening and target-guided synthesis: from structure to cellular activity.,17th RSC/SCI Medicinal Chemistry Symposium,Cambridge, UK,8th-11th September 2013.

Deprez-Poulain, R., Leroux, F., Piveteau, C., Charton, J., Dumont, J., Marechal, E., Bosc, D., Pottiez, V., Dassonneville, S., Hamdane, M., Hennuyer, N., Guo, Q., Liang, V., Tang, W. J., Staels, B., & Deprez, B. Modulators of Insulin Degrading Enzyme, from Structure to Function,Drug Discovery & Therapy World Congress 2013,3rd – 6th June 2013, Invited.

Bosc, D. Discovery via in situ click chemistry and structure activity relationships of inhibitors of Insulin-Degrading Enzyme.,Rencontres PRIM de la Chimie, de la Biologie et de la Physique,PRIM,28th May 2013, Lille, France.

Deprez, B. Chemical Control of the Bacterial Response to Antibiotics: a New Antibacterial Strategy.,Chemical Biology: Methods, Progress, Perspectives,the Vienna International Plant Conference Association,Vienna, Austria,11th-13th February 2013, Invited

2012

Bosc, D. Discovery of Insulin-Degrading Enzyme inhibitors via kinetic target-guided synthesis and orthogonal multicomponent partitioning.,6th Biological and Medicinal Chemistry Symposium,Cambridge, UK,14th December 2012.

Deprez, B. Pharmacocinétique exploratoire et imagerie moléculaire pour la validation de nouvelles cibles thérapeutiques.,4ème réunion annuelle de l'ITMO Technologies pour la santé,Aviesan,Lille, France,8th-9th October 2012, Invited.

Deprez-Poulain, R., Willand, N., Marechal, X., Bosc, D., Leroux, F., Charton, J., Villemagne, B., Wen, X., Elbakali, J., Berte, G., Tang, W. J., Baulard, A., Villeret, V., & Deprez, B. In situ protein-templated synthesis and fragment-based drug discovery, application to a bacterial transcriptional repressor and a human protease”,The 9th IUPAC International Symposium of Chemical Biology and 8th International Symposium,Beijing, China,25th-29th August 2012,Invited.

Flipo, M., Desroses, M., Piveteau, C., Leroux, F., Wohlkönig, A., Wintjens, R., Villeret, V., Veziris, N., Jarlier, V., Brodin, P., Baulard, A., Deprez, B., & Willand, N. Boosting Ethionamide as a new strategy to fight tuberculosis: in vitro and in vivo validation of 1,2,4-oxadiazole EthR inhibitors.,EFMC-ISMC 2012 22nd International Symposium on Medicinal Chemistry,Berlin, Germany,2nd-6th September 2012.

Deprez-Poulain, R. Inhibiteurs d'aggrécanase (ADAMTS-5) pour le traitement de l’arthrose.,3eme Forum Recherche, School of Pharmacy,Lille, France,6th-7th March 2012.

Willand, N. EthR as a new target to fight tuberculosis: exploration of a ligand binding pocket by combining structure-based drug design and in situ click-chemistry,Journée Commune SFC/SCT/ANP,Paris, France,6th Mar. 2012, Invited.

2011

Deprez, B. Drug to Genome to Drug: Discovery of new antiplasmodial compounds.,Annual One Day- Symposium on Medicinal Chemistry - Emerging Targets and treatments,SRC & KVCV,Ghent,25th November 2011, Invited.

Villemagne, B. Ethionamide Boosters as a New Strategy to Fight Tuberculosis,Journée Thématique d'Automne de la Société de Chimie Thérapeutique,Paris, France,15th Dec. 2011, Invited.

Deprez, B. Structure-based design of receptor and enzyme modulators: Case studies in drug-discovery and chemical biology.,25th Journées Franco-Belges de Pharmacochimie,Liège, Belgium,19-20th May 2011, Invited.

Gauriot, M., Charton, J., Leroux, F., Landry, V., Elbakali, J., Wen, X., Tang, W. J., Guo, Q., Deprez, B., & Deprez-Poulain, R. Découverte des premiers modulateurs de l'insulin-degrading enzyme,Scientific Day PRIM, Pasteur Institute,Lille, France,29th Mar 2011.

Jida, M., Laconde, G., Deprez-Poulain, R., & Deprez, B. An efficient synthesis of racemic and enantiomerically pure N-protected 2-substituted piperazines,Scientific Day PRIM, Pasteur Institute,Lille, France,29th Mar 2011.

Crauste, C. Mise au point d'une technique de résonance plasmonique de surface pour l'étude de l'interaction ligand-EthR (represseur transcriptionnel de M tuberculosis),Scientific Day PRIM, Pasteur Institute,Lille, France,29th Mar 2011.

Deprez, B. Les métiers de la recherche pour le pharmacien,Forum Industrie, Faculté de Pharmacie,Lille, France,3rd Mar 2011, Invited.

Deprez, B. Structure Based Discovery of receptor and enzyme modulators,CEA - CMBA,Grenoble, France,22nd Feb 2011, Invited.

2010

Deprez, B. U761 - Chemistry for health,Ghent,23rd Mar 2010, Invited.

Deprez-Poulain, R., Charton, J., Willand, N., Tang, W. J., Baulard, A., Villeret, V., & Deprez, B. Structure-based design of receptor and enzyme modulators: Case studies in drug-discovery and chemical biology.,BIT's 1st Annual International Conference of Medicinal Chemistry,Beijing, China,18-20 May 2010, Invited.

Villemagne, B. Validation of a Fragment-Based Drug Design approach for the rapid discovery of EthR inhibitors,Scientific Day PRIM,Lille,10th Mar 2010.

Maingot, L. Discovery of Novel Aggrecanase-2 inhibitors by HTS and hit-to-lead optimisation.,Scientific Day PRIM,Lille,10th Mar 2010.

Deprez-Poulain, R. First substrate-dependant modulators of insulin degrading enzyme,Journée Commune SFC/SCT/ANP,Paris,23rd Mar 2010, Invited.

Deprez, B. Découverte et sélection de médicament: domaines et itinéraires de recherche en pharmacie,Forum Recherche,Lille,3-4 Mar 2010,

Beghyn, T. Drug Morphing et repositionnement de médicaments: témoignage d’un pharmacien chef de projet,Forum Recherche,Lille,3-4 Mar 2010,

Totobenazara, J., Leroux, F., Landry, V., Tang, W. J., Deprez, B., Deprez-Poulain, R., & Charton, J. In situ click chemistry to discover IDE inhibitors,XVIIième Journée Jeunes Chercheurs SCT,Paris,5th February 2010, XVIIième Journée Jeunes Chercheurs SCT.

2009

Deprez, B. Taking up the ADME challenge in antimalarial drug discovery.,45th International Conference on Medicinal Chemistry RICT Drug Discovery and Selection.,Orleans, France,3-5th July 2009,

Deprez, B. Privileged Structures: Nature inspired compound design.,Protein-protein interactions: drug targets and methodological developments,Roscoff, France,15th June 2009, Roscoff, June 15-16, 2009.

Deprez-Poulain, R. Relever le défi de l'ADME: Etude de cas d'un inhibiteur de la metalloprotease PfAM1 comme antimalarique.,23èmes journées franco-belges de pharmacochimie,Mons, Belgium,May 29 2009.

2008

Willand, N., Dirié, B., Carette, X., Bifani, P., Singhal, A., Desroses, M., Flipo, M., Leroux, F., Deprez-Poulain, R., Frénois, F., Aumercier, M., Locht, C., Villeret, V., Baulard, A., & Deprez, B. A new strategy to fight tuberculosis: the discovery of thioamide drug boosters,ACS meeting, Philadelphia,American Chemical Society,Philadelphia,17-21 August 2008,

Deprez, B. Hit Finding: in situ chemistry,Gordon Research Conferences, Combinatorial Chemistry,Gordon Research Conferences,Oxford,August 31 - September 5 2008, invited.

2007

Willand, N., Dirié, B., Desroses, M., Carette, X., Villeret, V., Bifani, P., Baulard, A. R., & Deprez, B. EthR inhibitors as TB drug boosters: A new startegy to fight tuberculosis,New Drugs and Drug Candidates: Recent Achievements in Medicinal Chemistry, Annual One-Day Meeting on Medicinal Chemistry of SRC & KVCVUCB,LD Organisation,Braine-l'Alleud, Belgium,26th October 2007.

Deprez, B. EthR: Comment faire du neuf avec du vieux, l' ethionamide, un médicament contre la tuberculose,Joint Meeting of French Society of Chemistry, French Society of Medicinal Chemistry, Académie Nationale de Pharmacie,Paris,6th March 2007, Invited.

Deprez, B. Est-ce qu'EthR est une bonne cible thérapeutique,Pasteur Institute,IFR114,Lille, France,3rd Apr. 2007, Invited.

Deprez, B. Ligands du recepteur transcriptionnel EthR: une nouvelle stratégie contre la tuberculose,Sanofi Aventis,private communication to industry,Vitry-sur-Seine,22nd November 2007, Invited.

2006

Deprez-Poulain, R. Integration of synthesis, HTS and ADME data in an academic platform.,Meeting Accelrys,Paris, France,21 Nov. 2006, Invited.

Tartar, A. From hit to drug candidate: Drugability-based optimization,42èmes Rencontres Internationales de Chimie Thérapeutique, Marseille,Société de Chimie Thérapeutique,Marseille,5-7th July 2006, Invited.

Willand, N., Dirié, B., Hounsou, C., Baulard, A. R., Villeret, V., & Deprez, B. A novel strategy to fight tuberculosis,42èmes Rencontres Internationales de Chimie Thérapeutique,Marseille,05-07 Juillet 2006, Invited.

Deprez, B. La LC-MSMS un outil central pour la Lead-discovery,Forum labo Forum biotech,Paris, France,25 Apr. 2006, Invited.

2005

Deprez, B., & Willand, N. Nouvelles Approches pour la Conception de Médicaments; Diversité, complexité et activité des composés d’origine naturelle: un nouveau défi pour la chimie combinatoire,Academie Nationale de Pharmacie,Paris,31st Mai 2005, Invited.

Deprez, B. Biostructures & Drug Discovery; Chemical biology: Design smart compounds, validate targets, find new leads,Varian User group meeting,Paris,2005, Invited.

Deprez, B. Chimie pour le biologiste: Contraintes, sources d'inspiration & Mise en oeuvre,BioV1,Châtenay-Malaby,2005, Invited.

2004

Deprez-Poulain, R. Quelques outils de la chémogénomique: Application à la découverte d’une nouvelle cible antipaludique,Pasteur Institute,Journée Petits Déjeuners DrugDiscovery,Lille, France,19 Oct. 2004, Invited.

Gesquiere, J.-C. Synthèse d’hétérocycles adaptés à la préparation de chimiothèques combinatoires,3rd international meeting on heterocyclic chemistry,Tlemcen, Algérie,5-7 June 2004, Invited.

Gras-Masse, H. Synthetic lipopeptides: a viable approach for the therapeutic vaccines of the future?For the Prize Zervas of the ”European Peptide Society”, Prague, 3d International and 28th European Peptide Symposium,Prague,5-10 September 2004, Invited.

Deprez, B. Les conditions de la découverte: méthode et opportunités; Un nouveau regard sur les méthodes de la découverte du médicament,Colloque ACIP: Les voies de la découverte de Médicament:Où sont les molécules de demain?Paris,23rd June 2004, Invited.

Tartar, A. Panorama général de la « drug discovery » Les processus de la découverte du médicament: les voies prometteuses, les dogmes, les idées reçues, la place des biotechnologies,Colloque ACIP: Les voies de la découverte de Médicament:Où sont les molécules de demain?Paris,23rd June 2004, Invited.

Deprez, B. Information Rich Screening,Conference: Criblage Haut Débit: vers un criblage à haut contenu,Ecole thématique Biologie-Chimie-Informatique,Autrans, France,27th-29th September 2004, Invited.

Deprez, B. Privileged Structures,Euroscreen,Private communication to industry,Gosselies, Belgium,2004, invited.

2003

Dubs, P., Subra, G, Blanpain, A, Bourel, L, Melnyk, O, Gras-Masse, H, Martinez, J. Synthèse en parallèle de lipopeptides par ligation en utilisant de lanternes SynPhase®.Groupe Français des Peptides et des Protéines, 13e congrès, Anglet Biarritz,Anglet Biarritz,19-23 October 2003, Invited.

Gras-Masse, H. Lipid vector for the delivery of peptides towards intracellular pharmacological targets: example of the IFN-gamma receptor.,Cellular transport strategies for targeting of epitopes, drugs and reporter molecules, an International Workshop, Budapest, Hongrie,Budapest, Hongrie,6-9 Mars 2003, Invited.

Deprez, B. Partenaires-fournisseurs de l'industrie pharmaceutique,Forum Industrie, Faculté de Pharmacie,Lille, France,2003, Invited.

2002

Ryckebusch, A., Girault-Mizzi, S., Debreu-Fontaine, M.-A., Vandaele, R., Poulain-Déprez, R., Grellier, P., & Sergheraert, C. Localisation intra-parasitaire originale d’antipaludiques et conception d’une nouvelle bibliothèque de sulfonamides en série 4-aminoquinoléine.,French Society of Medicinal Chemistry,Paris, France,25 Jan. 2002.

Ryckebusch, A., Poulain-Déprez, R., Debreu-Fontaine, M.-A., Vandaele, R., Grellier, P., & Sergheraert, C. Localisation originale de 4-aminoquinoléines chez Plasmodium et conception d’une nouvelle bibliothèque de sulfonamides.,Bagnoles de l’Orne, France,28-30 May 2002.

2001

Bourel, L., Bonnet, D, Melnyk, O, Gras-Masse, H. Hydrazone ligation for the simultaneous lipidation of a multi-epitope peptide cocktail.,American peptide symposium,San Diego,Juillet 2001, American peptide symposium.

Gras-Masse, H. Toward a Second Generation of Multi-epitopic Lipopeptide Vaccines.,Vaccine Symposium, ACTG Meeting,14 Juillet 2001, Vaccine Symposium, ACTG Meeting.

Gras-Masse, H. Chemoselective Ligation and Antigen vectorization. Developments in Biologicals. Immunological Applications of Synthetic peptides.,Mérieux- Foundation-IABS,9-11 May 2001, Mérieux- Foundation-IABS.

Gras-Masse, H. Synthetic multiepitopic lipopeptide cocktails: a viable approach for the vaccines of the futur?Cedars-Sinai, Burns & Allens Research Institute,Los Angeles,15 June 2001, Cedars-Sinai, Burns & Allens Research Institute.

Gras-Masse, H. Towards a second generation of multiepitopic lipopeptide vaccines,Vaccine Symposium at the ACTG meeting,Arlington, Virginia,13-14 July 2001, Vaccine Symposium at the ACTG meeting.

Gras-Masse, H. Lipid-modified peptides for the modulation of intracellular pharmacological targets; Applications of novel chemoselective ligations to antigen vectorization,Elan Corporation,Dublin,11 Septembre 2001, Elan Corporation.

Gras-Masse, H. New development in chemoselective ligations: application to the delivery of peptide antigens,4th Australian Peptide Symposium, Queensland, Australia,Queensland, Australia,7-12 October 2001, 4th Australian Peptide Symposium.

Melnyk, O., Bourel, L., Grandjean, C., & Gras-Masse, H. Applications of a Novel Chemoselective Ligation Method to Antigen Vectorization,7th International Symposium, Solid Phase Synthesis, Southampton,Southampton,18-22 Septembre 2001, 7th International Symposium, Solid Phase Synthesis.

2000

Gras-Masse, H. Lipopeptides et cibles pharmacologiques intracellulaires,Laboratoire d’Histopathologie, Faculté de Médecine et Hôpital Erasme,Bruxelles,25 Janvier 2000,

1999

Gras-Masse, H. Lipopeptides as vaccines,Zeneca -Avecia,Manchester,4th February 1999,

Poulain, R. Pharmacologie in-vitro et synthèse automatisées: découverte et optimisation rapide de ligands du récepteur aux opiacés de type µ.Journée des Jeunes Chercheurs,French Society of Medicinal Chemistry,Paris, France,15 Jan. 1999,

Poulain, R., Williard, X., Horvath, D., & Déprez, B. Utilisation de la synthèse parallèle, du criblage et de la pharmacologie à hauts débits pour la découverte et l’optimisation de nouvelles têtes de série pharmaceutique.,French Society of Medicinal Chemistry,Rouen, France,7-9 Jul. 1999, Invited.

TOP